BioSpace News Archive

Taking an important step to accelerate innovation of new multidisciplinary solutions to address the growing global cancer burden, Varian Medical Systems announced it has entered into a definitive agreement to acquire Cancer Treatment Services International for $283 million.

MAZON: A Jewish Response to Hunger held a congressional briefing “Local Perspectives on Hunger in Rural America” on Thursday, May 16, 2019 with its Emerging Advocacy Fund (EAF) partners representing the most food-insecure states in the nation

Stability Growth announces the addition of seasoned executive David Lewis as chief operating officer and hiring plans for 20 additional full-time employees.

Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the first quarter ended March 31, 2019 and provided key business updates.

Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the presentation of data from its FIERCE-22 trial where vofatamab, the company’s lead therapeutic stimulates an increase in immune cell activation in patients with metastatic bladder cancer.

Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that an abstract describing clinical data regarding their lysine-specific demethylase (LSD1) inhibitor has been selected for an oral presentation at the 24th Congress of the European Hematology Association (EHA) to be held in Amsterdam, The Netherlands from June 13-16, 2019.

Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) (“Bellicum”) and certain of its officers.

Micronic widens the range of successful “hybrid” tubes. The leader in sample storage introduced 4 coding concepts, a tube with multiple sample identification methods, last year.

Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, today announced that it has moved to the Bio-Innovation Centre at the Cambridge Science Park, following the appointment of 15 new staff to its scientific and management teams including, Dr. Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer.

Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau for the treatment of neurodegenerative diseases, today announces the appointment of Dr Eric Yuen to its Board of Directors.